Sugi Predict

Sugi Predict / Targets / MRGPRX4

MRGPRX4

Mas-related G-protein coupled receptor member X4 · Q96LA9 · MRGPRX4 on Sugi Atlas →

91,660 patent compounds predicted against MRGPRX4, 43,819 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL45113 SCHEMBL45113 0.57 15/20
SCHEMBL220610 SCHEMBL220610 0.52 13/20
SCHEMBL223269 SCHEMBL223269 0.48 13/20
SCHEMBL243754 SCHEMBL243754 0.73 12/20
SCHEMBL79709 SCHEMBL79709 0.71 10/20
SCHEMBL202507 SCHEMBL202507 0.53 10/20
SCHEMBL69666 SCHEMBL69666 0.60 9/20
SCHEMBL182494 SCHEMBL182494 0.52 9/20
SCHEMBL229472 SCHEMBL229472 0.69 8/20
SCHEMBL130824 SCHEMBL130824 0.68 8/20
SCHEMBL257576 SCHEMBL257576 0.59 8/20
SCHEMBL79430 SCHEMBL79430 0.56 8/20
SCHEMBL79415 SCHEMBL79415 0.51 8/20
SCHEMBL257843 SCHEMBL257843 0.50 8/20
SCHEMBL8453 SCHEMBL8453 0.49 8/20
SCHEMBL46927 SCHEMBL46927 0.49 8/20
SCHEMBL202189 SCHEMBL202189 0.42 8/20
SCHEMBL214385 SCHEMBL214385 0.41 8/20
SCHEMBL182052 SCHEMBL182052 0.58 7/20
SCHEMBL257777 SCHEMBL257777 0.57 7/20

Clinical trials — most relevant to MRGPRX4 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The RECONSTRUCT Study - Reconstructing Disease Mechanisms in Asthma PHASE4COMPLETED
Investigation the Effect of Montelukast in COVID-19 PHASE2UNKNOWN
A Series of Pilot Studies to Evaluate the haemoDynamic and mEtabolic Effects oF apelIn aNd rElaxin PHASE2UNKNOWN
A Randomized, Double-Blind, Placebo-Controlled Study of Omalizumab for Idiopathic Anaphylaxis PHASE2COMPLETED
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase II Trail Evaluating the Efficacy and Safety of GR1802 Injection in Patients with Moderate to Severe Asthma PHASE2UNKNOWN
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine Prophylaxis PHASE2UNKNOWN
Exploration Of Key Targets And Biomarkers Involved In An Allergic Response In Subjects With Allergic Rhinitis (Hay Fever) PHASE1COMPLETED
A Phase 1 Study of GTX-B001 in Healthy Subjects and Patients With Chronic Inducible Urticaria PHASE1RECRUITING
Unraveling the Pathogenesis of Pruritus in Intrahepatic Cholestasis of Pregnancy nanUNKNOWN
Investigation of the Pruritogens of Liver-related Diseases nanUNKNOWN
Histamine Responsiveness in McCune-Albright Syndrome nanCOMPLETED
Selective Activation of the Adrenomedullin Receptors in Migraine nanNOT_YET_RECRUITING
The Severe Asthma Research Program III-Boston Clinical Site nanCOMPLETED
Molecular Mechanism of Asthma nanWITHDRAWN
The Real-world Treatment Satisfaction by Gefapixiant in RCC nanRECRUITING
Plasma Levels of CGRP and Expression of Specific microRNAs in Blood Cells of Episodic and Chronic Migraine Subjects nanCOMPLETED
BIOmarkers of MIGraine: a Proof of Concept Study Based on the Stratification of Responders to CGRP Monoclonal Antibodies nanCOMPLETED
Allergy and Immunology Natural History Study nanRECRUITING
Longitudinal Analysis of Amylin Levels in Migraine Patients Undergoing an Anti- CGRP/CGRPr Treatment nanNOT_YET_RECRUITING
Repeat Immunoadsorption Post Covid ME/CFS nanCOMPLETED
Assessment of CXCL5 Level in SLE Patients and Its Correlation with Disease Activity nanNOT_YET_RECRUITING
Searching for Novel Therapeutic Approaches in Migraine Patients Resistant to Treatments nanRECRUITING
B2 Adrenergic Receptor Gene Polymorphism in Bronchial Asthma nanUNKNOWN
CGRP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
In Vivo Assessment of Histamine Pharmacodynamics nanWITHDRAWN
Identification of an Asthma Susceptibility Gene on 3P nanCOMPLETED
The Role of Cytokines and Regulatory T Lymphocytes in Migraine Pathophysiology. nanRECRUITING
PACAP Induced Migraine Attacks in Patients With High and Low Genetic Load nanCOMPLETED
Thrombin Regulated Platelet Activation nanCOMPLETED
Clinical Characteristics and Pathophysiology of Post-Traumatic Headache nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a MRGPRX4 binder may also engage these)

ProteinNameSimilarity
Q96LB0 — 1.000 Q96LB0 →
Q4QXU3 — 1.000 Q4QXU3 →
Q7TN45 — 1.000 Q7TN45 →
Q2LL16 — 1.000 Q2LL16 →
Q4QXU4 — 1.000 Q4QXU4 →
MRGPRX1 Mas-related G-protein coupled receptor member X1 1.000 landscape →
Q4QXU6 — 1.000 Q4QXU6 →
Q4QXU5 — 1.000 Q4QXU5 →
Q4QXX9 — 1.000 Q4QXX9 →
Q5U9D9 — 0.998 Q5U9D9 →
Q4QXU2 — 0.997 Q4QXU2 →
Q4QXU0 — 0.996 Q4QXU0 →
MRGPRX2 Mas-related G-protein coupled receptor member X2 0.995 landscape →
Q7TN49 — 0.994 Q7TN49 →
Q91ZC6 — 0.994 Q91ZC6 →
Q91WW5 — 0.987 Q91WW5 →
Q91ZB9 — 0.986 Q91ZB9 →
Q3UG61 — 0.986 Q3UG61 →
Q91WW3 — 0.986 Q91WW3 →
Q91WW4 — 0.985 Q91WW4 →
Q91ZC0 — 0.985 Q91ZC0 →
Q8R4G1 — 0.985 Q8R4G1 →
Q8CIP3 — 0.984 Q8CIP3 →
Q91ZC4 — 0.982 Q91ZC4 →
Q7TN50 — 0.982 Q7TN50 →
Q91ZC5 — 0.982 Q91ZC5 →
Q3KNA1 — 0.981 Q3KNA1 →
Q3UG50 — 0.981 Q3UG50 →
Q91ZC7 — 0.979 Q91ZC7 →
Q8TDS7 — 0.976 Q8TDS7 →